Mechanisms for Lactobacillus rhamnosus treatment of intestinal infection by drug-resistant Escherichia coli

被引:2
|
作者
Li, Na [1 ]
Pang, Bing [1 ]
Li, Junjun [1 ]
Liu, Guanwen [1 ]
Xu, Xiaoguang [1 ]
Shao, Dongyan [1 ]
Jiang, Chunmei [1 ]
Yang, Baowei [2 ]
Shi, Junling [1 ]
机构
[1] Northwestern Polytech Univ, Sch Life Sci, Key Lab Space Biosci & Biotechnol, 127 Youyi West Rd, Xian 710072, Shaanxi, Peoples R China
[2] Coll Food Sci & Engn, 28 Xinong Rd, Yangling 712100, Shaanxi, Peoples R China
基金
国家重点研发计划;
关键词
LACTIC-ACID BACTERIA; CELL-SURFACE; ADHESION; BARRIER; PROBIOTICS; INTEGRITY; STRAINS; MYOSIN; MUCUS; GG;
D O I
10.1039/d0fo00128g
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The development of probiotics as therapeutic drugs is greatly important for the protection against threats of drug-resistant pathogen infection in both humans and animals. This study showed that Lactobacillus rhamnosus SHA113, previously isolated from breast milk of healthy humans, showed efficient therapeutic effects on infection by drug resistant Escherichia coli QBQ009. In addition to protecting the intestinal barrier via up-regulating the expression of tight junction proteins ZO-1 and occludin, it was also found that (1) both L. rhamnosus SHA113 and E. coli QBQ009 cells caused changes of the epithelial cell cytoskeleton and up-regulated the expression of phagocytosis-related proteins MYH2 in Caco-2 cells; however, only E. coli QBQ009 caused a strong decrease of cell viability. L. rhamnosus SHA113 treatment after E. coli QBQ009 infection significantly restored the damaged intestinal barrier and the changes of the epithelial cell cytoskeleton caused by E. coli QBQ009. (2) L. rhamnosus SHA113 showed a much higher adhesion rate to the intestinal tract and Caco-2 cells than E. coli QBQ009. The presence of E. coli QBQ009 significantly decreased the adhesion rate of L. rhamnosus SHA113, but not in reverse. (3) L. rhamnosus SHA113 had much higher self-coagulation than E. coli, and could strongly co-coagulate with E. coli QBQ009. The viability of E. coli QBQ009 greatly decreased after co-coagulation, while that of L. rhamnosus SHA113 was not influenced. (4) The polysaccharides produced by L. rhamnosus SHA113 significantly decreased the permeability of the intestinal tract and Caco2 cells, but had no remarkable influence on the adhesion rate of E. coli QBQ009. (5) Feeding L. rhamnosus SHA113 caused a significant reduction of Proteobacteria in the cecum of healthy mice, which was not significant in infected and treated mice. In summary, the decreased live pathogen amounts might be one of the decisive factors for the efficient cure of E. coli QBQ009 infection by L. rhamnosus SHA113, and the restoration of the intestinal barrier might be caused by the reduction of pathogens.
引用
收藏
页码:4428 / 4445
页数:18
相关论文
共 50 条
  • [41] Synergy Potential of Indole Alkaloids and Its Derivative against Drug-resistant Escherichia coli
    Dwivedi, Gaurav Raj
    Gupta, Shikha
    Maurya, Anupam
    Tripathi, Shubhandra
    Sharma, Ashok
    Darokar, Mahendra P.
    Srivastava, Santosh K.
    CHEMICAL BIOLOGY & DRUG DESIGN, 2015, 86 (06) : 1471 - 1481
  • [42] SANDBOXES AS A POTENTIAL SOURCE OF DENGEROUS DRUG-RESISTANT ESCHERICHIA COLI AND STAPHYLOCOCCUS AUREUS STRAINS
    Mazur, Edyta
    Chmiel, Maria Jolanta
    ADVANCEMENTS OF MICROBIOLOGY, 2021, 60 (01) : 77 - 89
  • [43] Transcriptomic Analysis Revealed Antimicrobial Mechanisms of Lactobacillus rhamnosus SCB0119 against Escherichia coli and Staphylococcus aureus
    Peng, Huan
    Zhou, Gang
    Yang, Xi-Miao
    Chen, Guo-Jun
    Chen, Hai-Bin
    Liao, Zhen-Lin
    Zhong, Qing-Ping
    Wang, Li
    Fang, Xiang
    Wang, Jie
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (23)
  • [44] Cefiderocol against Multi-Drug and Extensively Drug-Resistant Escherichia coli: An In Vitro Study in Poland
    Zalas-Wiecek, Patrycja
    Plachta, Katarzyna
    Gospodarek-Komkowska, Eugenia
    PATHOGENS, 2022, 11 (12):
  • [45] Treatment of drug-resistant tuberculosis
    Ajbani, Kanchan
    Soman, Rajeev
    Shetty, Anjali
    Rodrigues, Camilla
    LANCET INFECTIOUS DISEASES, 2011, 11 (09): : 660 - 660
  • [46] INFECTION WITH DRUG-RESISTANT TUBERCLE BACILLI
    THOMAS, OF
    BORTHWICK, WM
    HORNE, NW
    CROFTON, JW
    LANCET, 1954, 1 (JUN26): : 1308 - 1310
  • [47] INFECTION WITH DRUG-RESISTANT TUBERCLE BACILLI
    BECK, F
    AMERICAN REVIEW OF TUBERCULOSIS AND PULMONARY DISEASES, 1955, 72 (02): : 151 - 157
  • [48] INFECTION WITH DRUG-RESISTANT TUBERCLE BACILLI
    OWEN, D
    LANCET, 1954, 2 (JUL3): : 39 - 39
  • [49] TREATMENT OF DRUG-RESISTANT TUBERCULOSIS
    SENNEVILLE, E
    MEDECINE ET MALADIES INFECTIEUSES, 1995, 25 (03): : 369 - 376
  • [50] TREATMENT OF DRUG-RESISTANT TUBERCULOSIS
    BOREN, HG
    BUSEY, JF
    CORPE, RF
    GRZYBOWS.S
    NEWMAN, MM
    ORGANICK, AB
    LESTER, W
    AMERICAN REVIEW OF RESPIRATORY DISEASE, 1966, 94 (01): : 125 - &